TYBOST

Peak

cobicistat

NDAORALTABLET
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
21

Mechanism of Action

Cytochrome P450 3A Inhibitors

Pharmacologic Class:

Cytochrome P450 3A Inhibitor

Clinical Trials (5)

NCT06385119Phase 1Completed

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Volunteers.

Started Apr 2024
28 enrolled
Healthy Volunteer
NCT05494866Phase 1Terminated

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Started Dec 2022
6 enrolled
CYP3A InhibitorAdvanced Stage or Metastatic Pancreatic Ductal AdenocarcinomaPancreatic Cancer+2 more
NCT05197075Phase 1Completed

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Started Aug 2022
15 enrolled
Human Immunodeficiency Virus (HIV)
NCT05378906Phase 1Completed

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants

Started Jun 2022
32 enrolled
Healthy
NCT05236738Phase 1Completed

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

Started May 2022
42 enrolled
Healthy Participants

Loss of Exclusivity

LOE Date
Apr 6, 2033
86 months away
Patent Expiry
Apr 6, 2033
Exclusivity Expiry
Aug 22, 2026

Patent Records (4)

Patent #ExpiryTypeUse Code
8148374
Sep 3, 2029
SubstanceProduct
U-1279
8148374*PED
Mar 3, 2030
10039718
Oct 6, 2032
Product
10039718*PED
Apr 6, 2033